Verty's got it right (been lurking). - most won't see the positive in this release but that's not my problem & VRTX management shouldn't care either. Remember...to a CF patient or parent...all we want is to arrest the disease; To [theoretically] stop the lung related affects of CF in its tracks. Which, for a growing # of CF-ers, is what VRTX science delivers. Trust me...if I could halt my kids lung function at 87%...I'd take it and RUN! The only other option is to watch these patients is to get sicker and sicker by the day - right before your eyes. Last part of my rant...VRTX has the corrector/potentiator market until at least 2022 and IMO, once K + Lumacaftor revenues come in, they will be active buyers.